

University of Hawai‘i at Manoa
Studies Conducted by the Hawai‘i AIDS Clinical Research Program (HACRP)
Telephone Numbers: Oahu (808) 737-2751, Neighbor Islands (800) 806-8208
March/April 2009

Current Study	Purpose of Study	Description of Study and/or Drugs Used	Symptoms and/or Requirements	Information Contact
Treatment of HIV Gilead Study	To learn if elvitegravir, a new integrase inhibitor, is safe and useful in treating people failing their current anti-HIV treatment.	Randomized to receive either: Elvitegravir 150 mg 1x/day + other background anti-HIV drugs Vs. Raltegravir 400 mg 2x/day + other background anti-HIV drugs Compensation available.	HIV positive, on stable anti-HIV medication with HIV viral load > 1,000; at least 6 months experience to 2 classes of anti-HIV drugs; no past treatment with raltegravir.	Debbie 737-2751 Open
Cardiovascular Disease Study	To follow HIV positive people to see if inflammation and mitochondrial damage due to HIV may contribute to cardiovascular problems.	Observational study. The following will be done: EKG, DXA, CT scan, specialized CV ultrasound tests, blood work, oral glucose tolerance test, questionnaires. Compensation available.	HIV positive, 45 years of age or older, taking anti-HIV medication.	Jim, Lorna, Debbie 737-2751 Open early March
Treatment of Kaposi's sarcoma (KS) AMC Study	To evaluate the safety and effectiveness of an experimental oral drug, PTC299 on HIV-associated KS.	Phase 1: 3 different dose levels of PTC299 given in 28 day cycles up to 12 cycles. Phase 2: highest safe dose found in phase 1 given in 28 day cycles	HIV positive with biopsy proven skin KS lesions.	Cris 737-2751 Open
Endothelial Study	To determine if the treatment of low HDL will result in improvement of cardiovascular function.	Randomized to receive Niaspan (slow release niacin) for 12 weeks or no Niaspan. Ultrasound of Brachial artery will be done. Blood tests. Compensation available.	HIV positive. Taking anti-HIV drugs for 6 mo. at screening; HDL < 40 and LDL < 130; No diabetes; no use of lipid lowering drugs within 6 weeks of study entry.	Nancy 737-2751 Open
Macrophage Study	To compare the health of fat cells exposed to anti-HIV medications to fat cells not exposed to medication.	Fat biopsy, fasting blood work and DEXA scan. Compensation available.	HIV positive. Taking AZT, d4T ddI, tenofovir or abacavir. OR HIV positive and have never taken any anti-HIV medication OR HIV negative males.	Cris 737-2751 Open

You can find our web page on the internet: <http://www.hawaii.edu/hacrp/home2.htm>